1Wilson PW. Established risk factors and coronary artery disease : the Framingham Study[J]. Am J Hypertens, 1994,7 ( 7 Pt 2):7S-12S.
2Kozakova M, Palombo C, Pratali L, et al. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography[J]. Hypertension, 1997,29(2):551-559.
3Larouche I, Schiffrin EL. Cardiac microvasculature in DOCA-salt hypertensive rats: effect of endothelin ET (A) receptor antagonism [J]. Hypertension, 1999,34 : (4 pt 2) 795-801.
4Frohlich ED. Renin-angiotensin system inhibition improves coronary flow reserve in hypertension [J]. J Cardiovasc Pharmacol,2001,37 (Suppl 1) :S35-39.
6Kern MJ.Syndrome X.Understanding and evaluating the patient with chest pain and normal coronary arteriograms[J].Heart Dis Stroke,1992,1(5):299-302.
7Lim HE,Shim WJ,Rhee H.Assessment of coronary flow reserve with transthoracic Doppler echocardiography:comparison among adenosine,standard-does dipyridamole,and high-does dipyridamole[J].J Am Soc Echocardiogr,2000,13(4):264-270.
8Cannon RO,Epstein SE."Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries[J].Am J Cardiol,1988,61(15):1338-1343.
9Cannon RO,Schtnbe WH,Leon MB,et al.Limited coronary flow reserve after dipyridamole in patients with ergonovineinduced coronary vasoconstriction[J].Circulation,1987,75(1):163-174.
